Abstract
BackgroundLittle is known about the efficacy of booster COVID-19 vaccination in rituximab (RTX)-treated patients with autoimmune inflammatory rheumatic diseases (AIIRD).ObjectivesTo estimate COVID-19 breakthrough infection rate in AIIRD patients treated with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
